Cellectar Biosciences / Novelos Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2012. The filing is by Novelos Therapeutics, Inc., identified in the request as Cellectar Biosciences. Following the April 2011 reverse acquisition, Cellectar was the accounting acquirer; 2011 comparative results include Cellectar before the transaction and the combined company afterward.
Business context and financial performance
The company is a development-stage cancer-drug business focused on Cellectar’s compounds: LIGHT, a PET imaging agent; HOT, a radiotherapeutic; and COLD, a preclinical chemotherapy candidate. Development of legacy Novelos compounds NOV-002 and NOV-205 was suspended. The company reported no product revenue; gross margin is not applicable.
| Metric | Three months ended June 30, 2012 | Six months ended June 30, 2012 | Comparable 2011 period |
|---|---|---|---|
| Research and development | $1.315 million | $2.643 million | $0.962 million / $1.433 million |
| General and administrative | $0.897 million | $1.895 million | $0.797 million / $0.928 million |
| Merger costs | None | None | $0.496 million / $0.746 million |
| Net loss | $2.231 million | $4.588 million | $2.595 million / $3.560 million |
| Basic and diluted loss per share | $0.06 | $0.12 | $0.10 / $0.18 |
| Operating cash used | $3.200 million | $2.903 million for six months |
Six-month R&D rose 84%, primarily with resumed clinical, manufacturing and preclinical activity. Six-month G&A rose 104%, reflecting higher compensation, staffing and public-company costs. The quarterly net loss narrowed year over year, in part because 2011 included merger and convertible-note-related costs; the six-month loss increased as operating expenses grew and prior-year grant income and interest costs did not recur.
Cash, liquidity and capitalization
- At June 30, cash and cash equivalents were $7.146 million, versus $5.506 million at December 31, 2011; restricted cash was $55,000.
- Current assets were $7.340 million and current liabilities $0.636 million. Total liabilities were $1.219 million, including $450,000 of long-term notes payable and approximately $5,000 of capital lease obligations.
- Six-month operating cash use was $3.200 million. Financing activities provided $4.870 million net, primarily from the June 2012 public offering; investing activities used $29,000.
- The June offering raised $5.421 million gross and $4.871 million net through common shares and warrants. Common shares outstanding were 43.186 million at June 30 and 43.236 million as of August 7, 2012.
- There were 24.340 million warrants outstanding at June 30, in addition to 4.828 million options, creating potential dilution. The company had an accumulated deficit of $36.068 million.
Outlook, risks and contingencies
- Management expects continuing operating losses and stated that cash on hand should fund operations into the second quarter of 2013. Further execution of the operating plan depends on raising additional capital or completing a strategic transaction; there is no assurance funding will be available on acceptable terms or on time.
- LIGHT Phase 1–2 trials and the HOT Phase 1b dose-escalation trial were ongoing. Management expected to begin HOT Phase 2 in the third quarter of 2013 only if additional funding is obtained and an appropriate dose is established. These are forward-looking expectations, not assured milestones.
- Clinical, regulatory, manufacturing and financing risks are material; candidates may fail in development, and the company had no marketed products or product revenues.
- The NOV-002 securities class action was dismissed with prejudice; plaintiffs did not appeal by the deadline. In the BAM intellectual-property dispute, the court ruled for the company and dismissed BAM’s counterclaims, but BAM appealed. Management did not expect litigation contingencies to materially affect financial position, results or cash flows.
- The company reported $62,500 of second-quarter and $144,000 of six-month contributions to the University of Wisconsin, where its chief scientific officer is a faculty member; it also paid the university $51,290 and $144,044, respectively, for research and clinical-trial costs.
- Management concluded disclosure controls were effective as of June 30, 2012 and reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether available cash and actual spending support the stated runway into Q2 2013, and what financing alternatives are viable.
- Clinical progress, safety and dose findings for LIGHT and HOT, and whether funding enables the anticipated HOT Phase 2 timing.
- The terms and potential dilution from outstanding warrants and options, including the short-dated $1.00 warrants from the June offering.
- The status and potential consequences of BAM’s appeal, and any subsequent developments in other contingencies.
- Comparability of 2011 results given the reverse-acquisition accounting and merger-period presentation.